Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-01-09
2007-01-09
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S469000, C548S470000, C548S472000
Reexamination Certificate
active
10732702
ABSTRACT:
The present invention relates to spirobenzofuran lactam derivatives of the formula Iwhich are formed during fermentation by the microorganismStachybotris atraST002348, DSM 14952, processes for their preparation, their use as pharmaceuticals, and the microorganismStachybotris atraST002348, DSM 14952.
REFERENCES:
patent: 5366986 (1994-11-01), Sindelar et al.
patent: 6627604 (2003-09-01), Vertesy
patent: 1420528 (1976-01-01), None
Sakai et al (1998): STN International CAPLUS database, Columbus (Ohio), accession No.,1998: 627183.
Deng, et al., Total Synthesis and Structure Revision ofStachybotrys spirolactams, J. of Org. Chem.; 68; 2003; pp. 7422-7427.
Eppley, et al., Structures of Satratoxin F and Satratoxin G, Metabolites ofStachybotrys atra, J. of Org. Chem.; 45; 1980; pp. 2522-2523.
Kende, et al., Enantioselective Total Synthesis and Structure Revision of Spirohydrobenzofuranlactam 1. Total Sythesis of Stachybotrylactam, Organic Letters; 5(10; 2003; pp. 1785-1788.
Roggo, et al., Novel Spirohydrobenzofuranlactams as Antagonists of Endothelin and as Inhibitors of HIV-1 Protease Produced byStachybotryssp., J. of Antibiotics.; 49(4); 1996; pp. 374-379.
Brock T.D., et al., Microbial Genetics, Chapter 7., Biology of Microorganisms; Seventh Edition; Prentice Hall; 1994; pp. 238-247.
Charlton P., The Status of Plasminogen Acivator Inhibitor-1 as a Therapeutic Target, Expert Opinion on Investigational Drugs; vol. 6; No. 5; 1997; pp. 539-554.
Dawson S., et al., The Status of PAI-1 as a Risk Factor For Arterial and Thrombotic Disease: A Review, Atherosclerosis; vol. 95; 1992; pp. 105-117.
Declerck P.J., et al., Minisymposium: The Role of the Fibrinolytic System in the Pathophysiology and Treatment of Thrombosis, J. Internal Medicine; vol. 236; 1994; pp. 425-432.
Frankenne F., et al, Molecular Interactions Involving Urokinase Plasminogen Activator (uPA), Its Receptor (uPAR) and Its Inhibitor, Plasminogen Activator Inhibitor-1 (PAI-1), As New Targets For Tumour Therapy, Emerging Therapeutic Targets; vol. 3; No. 3; 1999; pp. 469-481.
Stolp H., Dispersal of Microorganisms and Development of Microbial Populations., Microbial Ecology Organisms, Habitats, Activities, Chapter 6.; Cambridge University Press; 1988; pp. 172-180.
Vassalli J.D., et al, The Plasminogen Activator/Plasmin System, J. Clin. Invest; vol. 88; Oct. 1991; pp. 1067-1072.
Vertesy L., et al., Memnopeptide A, a Novel Terpene Peptide From Memnoniella With an Activating Effect On SERCA2, Journal Of Antibiotics; vol. 54; No. 10; Oct. 2001; pp. 771-782.
Salt Formation, Chapter 76, Remington Pharmaceutical Sciences; 17th Edition; 1985; p. 1418.
Eder Claudia
Kurz Michael
Toti Luigi
Lin Jiang
Ort Ronald G.
Sanofi-Aventis Deutschland GmbH
Shameem Golam M. M.
LandOfFree
Spirobenzofuran lactams and their derivatives, processes for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Spirobenzofuran lactams and their derivatives, processes for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Spirobenzofuran lactams and their derivatives, processes for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3809941